Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Global Rhinovirus Infections Market 2016 Share, Trend, Segmentation and Forecast to 2022

Monday, October 10, 2016 4:47
% of readers think this story is Fact. Add your two cents.

(Before It's News)


Global Markets Direct’s, ‘Rhinovirus Infections – Pipeline Review, H2 2016’, provides an overview of the Rhinovirus Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rhinovirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhinovirus Infections and features dormant and discontinued projects.

Complete report details @

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Rhinovirus Infections 
- The report reviews pipeline therapeutics for Rhinovirus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Rhinovirus Infections therapeutics and enlists all their major and minor projects 
- The report assesses Rhinovirus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Rhinovirus Infections

Request a sample report @

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Rhinovirus Infections 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Rhinovirus Infections pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @

Key points in table of content

Table of Contents 
Table of Contents 2 
List of Tables 4 
List of Figures 4 
Introduction 5 
Global Markets Direct Report Coverage 5 
Rhinovirus Infections Overview 6 
Therapeutics Development 7 
Pipeline Products for Rhinovirus Infections – Overview 7 
Pipeline Products for Rhinovirus Infections – Comparative Analysis 8 
Rhinovirus Infections – Therapeutics under Development by Companies 9 
Rhinovirus Infections – Therapeutics under Investigation by Universities/Institutes 10 
Rhinovirus Infections – Pipeline Products Glance 11 
Clinical Stage Products 11 
Early Stage Products 12 
Rhinovirus Infections – Products under Development by Companies 13 
Rhinovirus Infections – Products under Investigation by Universities/Institutes 14 
Rhinovirus Infections – Companies Involved in Therapeutics Development 15 
AIMM Therapeutics B.V. 15 
AstraZeneca Plc 16 
Aviragen Therapeutics, Inc. 17 
Biological Mimetics, Inc. 18 
Boehringer Ingelheim GmbH 19 
Novartis AG 20 
Rhinovirus Infections – Therapeutics Assessment 21 
Assessment by Monotherapy Products 21 
Assessment by Target 22 
Assessment by Mechanism of Action 24 
Assessment by Route of Administration 26 
Assessment by Molecule Type 28 
Drug Profiles 30 
BNT-014 – Drug Profile 30 
Product Description 30 
Mechanism Of Action 30 
R&D Progress 30 
KR-22809 – Drug Profile 32 
Product Description 32 
Mechanism Of Action 32 
R&D Progress 32 
Monoclonal Antibodies to Inhibit Viral 3C Protease for Human Rhinovirus Infections – Drug Profile 33 
Product Description 33 
Mechanism Of Action 33 
R&D Progress 33 
Monoclonal Antibody for Human Rhinovirus Infections – Drug Profile 34 
Product Description 34 
Mechanism Of Action 34 
R&D Progress 34 
OBR-5340 – Drug Profile 35 
Product Description 35 
Mechanism Of Action 35 
R&D Progress 35 
PL-402 – Drug Profile 36 
Product Description 36 
Mechanism Of Action 36 
R&D Progress 36 
Polymer for Viral Infections – Drug Profile 37 
Product Description 37 
Mechanism Of Action 37 
R&D Progress 37 
Recombinant Peptide for Rhinovirus Infection – Drug Profile 38 
Product Description 38 
Mechanism Of Action 38 
R&D Progress 38 
Small Molecule to Inhibit PI4KIII beta for Rhinovirus Infection – Drug Profile 39 
Product Description 39 
Mechanism Of Action 39 
R&D Progress 39 
Small Molecules to Inhibit 3C Protease for Rhinovirus Infection – Drug Profile 40 
Product Description 40 
Mechanism Of Action 40 
R&D Progress 40 
vapendavir – Drug Profile 41 
Product Description 41 
Mechanism Of Action 41 
R&D Progress 41 
Rhinovirus Infections – Dormant Projects 44 
Rhinovirus Infections – Product Development Milestones 45 
Featured News & Press Releases 45 
Mar 03, 2015: Biota Commences Dosing in Vapendavir SPIRITUS Phase 2b Trial 45 
Mar 28, 2012: Biota Announces Positive Phase IIb Data In Asthma Patients With Human Rhinovirus Infection 45 
Appendix 47 
Methodology 47 
Coverage 47 
Secondary Research 47 
Primary Research 47 
Expert Panel Validation 47 
Contact Us 47 
Disclaimer 48

List of Tables 
Number of Products under Development for Rhinovirus Infections, H2 2016 7 
Number of Products under Development for Rhinovirus Infections – Comparative Analysis, H2 2016 8 
Number of Products under Development by Companies, H2 2016 9 
Number of Products under Investigation by Universities/Institutes, H2 2016 10 
Comparative Analysis by Clinical Stage Development, H2 2016 11 
Comparative Analysis by Early Stage Development, H2 2016 12 
Products under Development by Companies, H2 2016 13 
Products under Investigation by Universities/Institutes, H2 2016 14 
Rhinovirus Infections – Pipeline by AIMM Therapeutics B.V., H2 2016 15 
Rhinovirus Infections – Pipeline by AstraZeneca Plc, H2 2016 16 
Rhinovirus Infections – Pipeline by Aviragen Therapeutics, Inc., H2 2016 17 
Rhinovirus Infections – Pipeline by Biological Mimetics, Inc., H2 2016 18 
Rhinovirus Infections – Pipeline by Boehringer Ingelheim GmbH, H2 2016 19 
Rhinovirus Infections – Pipeline by Novartis AG, H2 2016 20 
Assessment by Monotherapy Products, H2 2016 21 
Number of Products by Stage and Target, H2 2016 23 
Number of Products by Stage and Mechanism of Action, H2 2016 25 
Number of Products by Stage and Route of Administration, H2 2016 27 
Number of Products by Stage and Molecule Type, H2 2016 29 
Rhinovirus Infections – Dormant Projects, H2 2016 44

Get this report @

Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.